Progression of fibrosis in advanced chronic hepatitis C: Evaluation by morphometric image analysis†
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Fibrosis progression in chronic liver disease has usually been evaluated by liver biopsy using insensitive semiquantitative numerical scores. An alternative to this is to measure fibrous tissue quantitatively using morphometric image analysis. The aim of this study was to quantify fibrosis progression in a cohort of patients with treatment-refractory chronic hepatitis C enrolled in a placebo-controlled clinical trial of interferon gamma-1b (IFN-gamma 1b) for the treatment of advanced hepatic fibrosis. We used morphometry to quantify the amount of fibrous tissue in liver biopsies performed at baseline and after 48 weeks in 245 patients who had paired unfragmented, adequate-sized specimens and correlated the results with clinical and laboratory parameters. Eighty-seven patients were treated with placebo and 158 with IFN-gamma 1b. No effect of the drug on fibrosis was found in the trial, and so data from all 245 patients were combined for analysis. At baseline, 78% had cirrhosis; 22%, bridging fibrosis. The mean morphometrically determined collagen content increased by 58% between baseline and 48 weeks. There were statistically significant but weak correlations of fibrosis with platelet count, albumin, bilirubin, INR, and hyaluronic acid; however, changes in these did not correlate with or predict changes in fibrosis in the liver biopsy. CONCLUSION: In advanced chronic hepatitis C, fibrosis increases at a rapid pace that can only be detected by morphometry. This technique can be used in future therapeutic trials of agents to inhibit fibrosis progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011 · cited 1×
“0001) at each of the three baseline Ishak fibrosis stages (4-6).”
BackgroundRates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
Poynard, T., Ratziu, V., Charlotte, F., Goodman, Z., McHutchison, J., & Albrecht, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00097-0 · Cited by 749
Self-citation
Cited by
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Grading and staging systems for inflammation and fibrosis in chronic liver diseases
Goodman, Z. D. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.006 · Cited by 884
Self-citationTherapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
Asgharpour, A., Cazanave, S. C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B. A., Kumar, D. P., Daita, K., Min, H.-K., Mirshahi, F., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.005 · Cited by 538
“Research Article typical of human NASH [3].”
MethodDiagnosis and Quantitation of Fibrosis
Manning, D. S., & Afdhal, N. H. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.001 · Cited by 399
Self-citationLimitations of non-invasive tests for assessment of liver fibrosis
Patel, K., & Sebastiani, G. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100067 · Cited by 317
Calvaruso, V., Burroughs, A. K., Standish, R., Manousou, P., Grillo, F., Leandro, G., Maimone, S., Pleguezuelo, M., Xirouchakis, I., Piero Guerrini, G., et al. (2009) · Hepatology · doi:10.1002/hep.22745 · Cited by 289
Fontana, R. J., Goodman, Z. D., Dienstag, J. L., Bonkovsky, H. L., Naishadham, D., Sterling, R. K., Su, G. L., Ghosh, M., & Wright, E. C. (2008) · Hepatology · doi:10.1002/hep.22099 · Cited by 179
Self-citationNaoumov, N. V., Brees, D., Loeffler, J., Chng, E., Ren, Y., Lopez, P., Tai, D., Lamle, S., & Sanyal, A. J. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.018 · Cited by 115
Beyond scoring: a modern interpretation of disease progression in chronic liver disease
Rosselli, M., MacNaughtan, J., Jalan, R., & Pinzani, M. (2013) · Gut · doi:10.1136/gutjnl-2012-302826 · Cited by 96
A critical review of endpoints for non-cirrhotic NASH therapeutic trials
Ratziu, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.001 · Cited by 74
Pan, J. J., Bao, F., Du, E., Skillin, C., Frenette, C. T., Waalen, J., Alaparthi, L., Goodman, Z. D., & Pockros, P. J. (2018) · Hepatology Communications · doi:10.1002/hep4.1228 · Cited by 70
“ALT (n = 80) 122 122 (30-664) 123 (22-439) 0.”
MethodSelf-citationKao, Y.-H., Lin, Y.-C., Lee, P.-H., Lin, C.-W., Chen, P.-H., Tai, T.-S., Chang, Y.-C., Chou, M.-H., Chang, C.-Y., & Sun, C.-K. (2020) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-020-00274-4 · Cited by 17
Metadata
- Authors
- Goodman, Z. D., Becker, R. L., Pockros, P. J., & Afdhal, N. H.
- Venue
- Hepatology
- Published
- 2007-04
- Volume
- 45
- Issue
- 4
- Pages
- 886-894
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2033523638
- Cited by
- 145
- References
- 3
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.